For decades, scientists have known that elevated CA19-9, a complex sugar structure that coats many proteins, was a biomarker for pancreatic cancer, but only recently did Dr. Engle and her colleagues at the Salk Research Institute discover that CA19-9 is directly involved in causing pancreatitis. CA19-9 is expressed in low levels in normal pancreatic ducts and becomes dramatically elevated locally and systemically in patients with pancreatic disease.

MCC invested in RMS to advance treatments for all types of diabetes, starting with Type 3c. Less common than Type 1 or Type 2 diabetes, Type 3c diabetes, also referred to as “pancreatogenic” diabetes, results from a pancreatic condition such as chronic pancreatitis, cystic fibrosis, pancreatic cancer or a total pancreatectomy.

Ariel Precision Medicine (Ariel) is a genomic health information technology company that is spearheading a new approach to complex disease care using precision medicine for the diagnosis, monitoring & tailored treatment of complex disease, starting with pancreatitis, pancreatic cancer, gastrointestinal and other complex diseases.